National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 37461-37462 [2020-13388]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 120 / Monday, June 22, 2020 / Notices
Date: July 15, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 1206, Bethesda, MD 20892
(Teleconference).
Contact Person: John C. Pugh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1206,
Bethesda, MD 20892, (301) 435–2398,
pughjohn@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Intellectual Property
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be the United States only
and the field of use may be limited to
the following:
‘‘Treatment of neuropathic and/or
ischemic skin ulcers in humans’’.
This technology discloses a topical
ointment formulation comprising about
.5% to 3.0% by weight non-acidified
sodium nitrite dispersed in white
petrolatum, mineral oil and bisabolol for
topical administration. Nitrite anions
may act as a vasodilator in vivo by
generating nitric oxide (NO) in tissues
with lower oxygen tension and pH.
Therapeutic application of sodium
nitrite through this specific topical
formulation may provide selective
vasodilation to hypoxemic tissue that
treat ulcers associated with chronic
ischemic and neuropathic ulcer
conditions associated with several
diseases.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
[FR Doc. 2020–13324 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Ointment for the
Topical Administration to Ischemic
Treat and/or Neuropathic Ulcers in
Humans
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Emmaus
Medical Inc. located in 21250
Hawthorne Boulevard, Suite 800,
Torrance, CA, 90503.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 7, 2020 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Edward Fenn, Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, Telephone:
240–276–6833 or Email: Tedd.Fenn@
nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
VerDate Sep<11>2014
18:08 Jun 19, 2020
Jkt 250001
I. United States Provisional Patent
Application No. 62/077,622 filed Nov. 10,
2014, ‘‘Topical Sodium Nitrite
Formulations’’, [HHS Ref. No. E–149–2014–
0–US–01];
II. International Patent Application No.
PCT/US2015/060015 filed Nov. 10, 2015,
‘‘Topical Sodium Nitrite Formulations’’,
[HHS Reference No. E–149–2014–0–PCT–02];
III. European National Stage Patent
Application No. 15798623.3, filed Nov. 10,
2015, ‘‘Topical Sodium Nitrite
Formulations’’, [HHS Ref. No. E–149–2014–
0–EP–03];
IV. U.S. National Stage Patent Application
No. 15/525,557 filed May 9, 2017, ‘‘Topical
Sodium Nitrite Formulations’’, [HHS Ref. No.
E–149–2014–0–US–04];
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
37461
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: June 12, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–13315 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Opportunities for Collaborative Research at
the NIH Clinical Center.
Date: July 23, 2020.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Telephone Conference Call).
Contact Person: YingYing Li-Smerin, MD,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 207–
P, Bethesda, MD 20892–7924, (301) 827–
7942, lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Grant Review for NHLBI K Award Recipients.
Date: July 24, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20814 (Telephone Conference Call).
Contact Person: Michael P Reilly, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 208–Z,
Bethesda, MD 20892, (301) 827–7975,
reillymp@nhlbi.nih.gov.
E:\FR\FM\22JNN1.SGM
22JNN1
37462
Federal Register / Vol. 85, No. 120 / Monday, June 22, 2020 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–13387 Filed 6–19–20; 8:45 am]
National Institute of Allergy and
Infectious Diseases Notice of Closed
Meeting
BILLING CODE 4140–01–P
Dated: June 17, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–13388 Filed 6–19–20; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning and Implementation Grants (R34
and U01).
Date: July 16, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F58, Rockville, MD
20852, cerritem@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS).
VerDate Sep<11>2014
18:08 Jun 19, 2020
Jkt 250001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Centers of Excellence for
Influenza Research and Response.
Date: July 14–15, 2020.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13B,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Yong Gao, Ph.D., Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3G13B, Rockville, MD 20892–
7616, (240) 669–5048, gaoL2@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–13326 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: July 27–29, 2020.
Time: 8:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F40B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Kelly Y. Poe, Ph.D.,
Deputy Director, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3F40B, Bethesda, MD 20892–
9834, (240) 669–5036, poeky@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–13323 Filed 6–19–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 85, Number 120 (Monday, June 22, 2020)]
[Notices]
[Pages 37461-37462]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13388]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Opportunities for Collaborative Research at
the NIH Clinical Center.
Date: July 23, 2020.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 207-P, Bethesda, MD 20892-7924, (301) 827-7942,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Grant Review for NHLBI K Award Recipients.
Date: July 24, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20814 (Telephone Conference Call).
Contact Person: Michael P Reilly, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7975,
[email protected].
[[Page 37462]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: June 17, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-13388 Filed 6-19-20; 8:45 am]
BILLING CODE 4140-01-P
